Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 8/20 | 0.58 |
| ▸ | ERN1 | O75460 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | DHPS | P49366 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30197462 | 1.00 | CYP2A6 (0.58) | CYP2A6ERN1NPC1RAB9AALDH1A1 | |
| SCHEMBL2019385 | 0.85 | CYP2A6 (0.62) | CYP2A6ERN1RAB9AALDH1A1DYRK1A | |
| SCHEMBL23775695 | 0.78 | CYP2A6 (0.60) | CYP2A6RAB9AALDH1A1 | |
| SCHEMBL4385517 | 0.77 | CYP2A6 (0.58) | CYP2A6ERN1NPC1RAB9AALDH1A1 | |
| SCHEMBL21234909 | 0.77 | CYP2A6 (0.58) | CYP2A6MAPTHTT | |
| SCHEMBL6963606 | 0.77 | CYP2A6 (0.58) | CYP2A6NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL20391352 | 0.77 | CYP2A6 (0.58) | CYP2A6ALDH1A1 | |
| SCHEMBL28086785 | 0.77 | CYP2A6 (0.73) | CYP2A6NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL12683402 | 0.77 | CYP2A6 (0.61) | CYP2A6 | |
| SCHEMBL7972992 | 0.77 | RAB9A (0.38) | CYP2A6ERN1NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117305308-A | High-stability nucleic acid aptamer molecule, and compound and application thereof | 华东理工大学 | 2023-12-29 | — | — | CN | disclosed |
| EP-3647311-B1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-11-01 | — | — | EP | disclosed |
| CN-115974762-B | Diamine monomer with bulky alkynyl side group, polybenzoxazole precursor, photosensitive resin composition and application thereof | 波米科技有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-115626890-B | Diamine monomer with bulky alkynyl side group, and preparation method and application thereof | 波米科技有限公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-115974762-A | Diamine monomer with bulky alkynyl side group, polybenzoxazole precursor, photosensitive resin composition and application thereof | 波米科技有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-115704025-A | Novel nucleic acid molecule detection and quantification technology | 华东理工大学 | 2023-02-17 | — | — | CN | disclosed |
| CN-115626890-A | Diamine monomer with bulky alkynyl side group and preparation method and application thereof | 波米科技有限公司 | 2023-01-20 | — | — | CN | disclosed |
| EP-3421465-B1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AS WELL AS PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2022-10-26 | — | — | EP | disclosed |
| CN-111592472-B | Fluorescent dye and preparation method and application thereof | 纳莹(上海)生物科技有限公司 | 2022-10-21 | — | — | CN | disclosed |
| EP-3421464-B1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AS WELL AS PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2021-11-24 | — | — | EP | disclosed |
| US-7863302-B2 | Compounds and methods for modulating FX-receptors | ELI LILLY AND COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
| US-20080306125-A1 | Compounds and Methods for Modulating Fx-Receptors | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2008-12-11 | — | — | US | disclosed |
| EP-1984360-A2 | COMPOUNDS AND METHODS FOR MODULATING FX-RECEPTORS | Eli Lilly & Company (US) | 2008-10-29 | — | — | EP | disclosed |
| US-7339065-B2 | Design and synthesis of optimized ligands for PPAR | BETHESDA PHARMACEUTICALS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7339065-B2 | Design and synthesis of optimized ligands for PPAR | BETHESDA PHARMACEUTICALS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| WO-2007092751-A2 | COMPOUNDS AND METHODS FOR MODULATING FX-RECEPTORS | ELI LILLY AND COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
| US-20070099969-A1 | Design and synthesis of optimized ligands for ppar | THE UNIVERSITY OF MISSISSIPPI | 2007-05-03 | — | — | US | disclosed |
| US-20070099969-A1 | Design and synthesis of optimized ligands for ppar | THE UNIVERSITY OF MISSISSIPPI | 2007-05-03 | — | — | US | disclosed |
| WO-2001090105-A1 | ISOTHIAZOLES AS PESTICIDES | SYNGENTA LIMITED (GB) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306125-A1 | Compounds and Methods for Modulating Fx-Receptors | F2R, TBXA2R, PTAFR | CYP2A6 731/4885ERN1 3507/4885NPC1 426/4885 |
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | CYP2A6 1871/4885ERN1 2555/4885NPC1 2935/4885 |
| US-20070099969-A1 | Design and synthesis of optimized ligands for ppar | PPARD, PPARA, PPARG | CYP2A6 133/4885ERN1 4155/4885NPC1 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.